Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 Nov-Dec;28(6):277-9.
doi: 10.1097/01.wnf.0000192136.46145.44.

Efficacy of topiramate and valproate in chronic migraine

Marco Bartolini  1 , Mauro Silvestrini, Ruja Taffi, Chiara Lanciotti, Roberta Luconi, Marianna Capecci, Leandro Provinciali
Affiliations
Clinical Trial

Efficacy of topiramate and valproate in chronic migraine

Marco Bartolini et al. Clin Neuropharmacol. 2005 Nov-Dec.

Abstract

Objectives: The aim of this study was to compare the efficacy of sodium valproate and topiramate in treating chronic migraine.

Methods: Forty-nine patients with chronic migraine were randomly assigned to 1 of 2 groups of treatment: 750 mg/day valproate or 75 mg/day topiramate. Efficacy variables were number of days with headache over a 30-day period and changes in Migraine Disability Assessment (MIDAS) scores at 3 months.

Results: At baseline the 2 groups had similar numbers of days with headache and mean MIDAS scores. At the end of the treatment period, a significant reduction in 30-day headache frequency with respect to baseline (P < 0.00001) and a significant reduction in MIDAS scores (P < 0.00001) were recorded in both groups. There were no significant differences in beneficial effects between the 2 drugs.

Discussion: Valproate and topiramate seem to be able to manage successfully chronic migraine without substantial differences in efficacy and tolerability. This affords clear practical advantages-in the event of failure of or intolerance for one treatment, the patient may be switched to the other.

PubMed Disclaimer